论文部分内容阅读
一份发表于美国《科学》杂志的基因治疗癌症的最新研究报告指出,将体外靶向肿瘤细胞的遗传工程学修饰的自身淋巴细胞回输给患者体内治疗,可使晚期皮肤癌患者肿瘤得以衰退。这是利用基因技术治疗癌症研究的重大突破,为人类治愈癌症带来新的希望。不过,也有科学家认为对这一结果不要太过乐观,这仅仅是攻克癌症进程中的第一步。来自于美国癌症研究所的科学家们对17例黑素瘤患者进行了试验。研究人员通过修饰患者自身白细胞来识别并破坏癌细胞;其中,被修饰的T细胞为白细胞的一种,可在免疫系统中起重要作用,识别体内特定的外来抗原,激活或杀死其他免疫细胞,但由于癌细胞与健康细胞外观相似,致使T细胞识别难以凑效。
A recent study published in the journal Science in the United States for gene therapy of cancer states that reintroducing genetically engineered lymphocytes modified in vitro targeted to tumor cells into the body of patients can result in the regression of tumors in patients with advanced skin cancer . This is a major breakthrough in the use of genetic technology to treat cancer research and bring new hope to human beings to cure cancer. However, some scientists think that this result should not be too optimistic, this is just the first step in the process of cancer capture. Scientists from the American Cancer Institute tested 17 patients with melanoma. Researchers identify and destroy cancer cells by modifying the patient’s own white blood cells. Among them, the modified T cells are a type of white blood cells that play an important role in the immune system, recognize specific foreign antigens in the body, activate or kill other immune cells , But due to the similar appearance of cancer cells and healthy cells, it is difficult to identify T cells.